POSTNEOADJUVANT THERAPY STAGE IIIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for POSTNEOADJUVANT THERAPY STAGE IIIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new POSTNEOADJUVANT THERAPY STAGE IIIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for POSTNEOADJUVANT THERAPY STAGE IIIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo tested for Tough-to-Treat stomach cancers
Disease control Recruiting nowThis early-stage study is testing whether combining two existing drugs, pembrolizumab and lenvatinib, can help control advanced stomach or gastroesophageal cancers that have spread or cannot be surgically removed. The trial is for adults whose cancer has continued to grow despite…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IIIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New drug duo tested to fight advanced GI cancers
Disease control Recruiting nowThis early-stage study aims to find the safest and most effective dose of a new two-drug combination for people with advanced colorectal or gastroesophageal (stomach/esophagus) cancers that have spread. The trial will enroll about 45 adults whose cancer has progressed after at le…
Matched conditions: POSTNEOADJUVANT THERAPY STAGE IIIB GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC